No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
US Health Agencies Recommend Pausing Valneva's Chikungunya Vaccine For Older Adults After Adverse Events
US Recommends Pause in Valneva's Chikungunya Vaccine Use
Valneva Provides Update on Recommended Use of IXCHIQ by Elderly Individuals in the United States
Guggenheim Maintains Valneva(VALN.US) With Buy Rating, Cuts Target Price to $14
Valneva Is Maintained at Buy by Guggenheim
Valneva Analyst Ratings